Skip to main content
. 2016 Dec 27;8(4):6663–6680. doi: 10.18632/oncotarget.14255

Figure 1. Serum IL-17A and GM-CSF are elevated in TSCC patients.

Figure 1

Serum levels of IL-17A A. GM-CSF B. IL-6 C. and TGF-β1 D. in healthy controls and TSCC patients. E. Serum IL-17A levels in TSCC patients with or without lymph node metastasis. F. Serum IL-17A levels in TSCC patients in early or advanced stage. G. Serum IL-17A levels in TSCC patients of different histological grade. H. Serum IL-17A levels in TSCC patients of different tumor size. I. Serum GM-CSF levels in TSCC patients with or without lymph node metastasis. J. Serum GM-CSF levels in TSCC patients in early or advanced stage. K. Serum GM-CSF levels in TSCC patients of different histological grade. L. Serum GM-CSF levels in TSCC patients of different tumor size. Open circles represent each subject and vertical lines indicate mean ± SEM. *P < 0.05 and **P < 0.01 compared with controls. N0: no regional lymph node metastasis; N1-N2: metastasis in a single, multiple ipsilateral or bilateral lymph node. T1: < 2 cm; T2: > 2, < 4 cm; T3: > 4 cm; T4: massive tumor which invades adjacent structures.